Sonnet BioTherapeutics (SONN) announced positive findings from the first safety review of the expansion cohort in its Phase 1 SB101 clinical ...
The drug candidates comprise modified versions of recombinant human interleukin ... connected to the company’s Fully Human Albumin Binding (FHAB) platform. Another drug, SON-1400 is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback